Apr 07, 2025 7:00am EDT iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline
Jan 07, 2025 7:00am EST iBio Discovers Novel Antibody Targeting Activin E in Collaboration with AstralBio
Jan 02, 2025 7:00am EST iBio Expands Cardiometabolic and Obesity Program with Anti-Myostatin Antibody Discovered Using its Proprietary Platform, In-Licensed from AstralBio
Sep 20, 2024 4:05pm EDT iBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update
